MA30510B1 - Nouveau cristal d'acide 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]propionique - Google Patents

Nouveau cristal d'acide 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]propionique

Info

Publication number
MA30510B1
MA30510B1 MA31468A MA31468A MA30510B1 MA 30510 B1 MA30510 B1 MA 30510B1 MA 31468 A MA31468 A MA 31468A MA 31468 A MA31468 A MA 31468A MA 30510 B1 MA30510 B1 MA 30510B1
Authority
MA
Morocco
Prior art keywords
hydroxybenzoyl
cyclopentyloxy
methoxy
hydroxy
benzisoxazol
Prior art date
Application number
MA31468A
Other languages
English (en)
Inventor
Kenji Yonezawa
Hironori Kotsubo
Yasutaka Baba
Yukie Tada
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of MA30510B1 publication Critical patent/MA30510B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Le cristal de l'acide 3-{5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-l,2-benzisoxazol-6-yl)méthoxy]phényl}propionique ayant des pics à la position 14.0, 16.0, 23.3, 23.7 et 26.3° et le cristal de l'acide 3-{5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-l,2-benzisoxazol-6-yl)méthoxy] phényl}propionique ayant des pics à la position 14.6, 23.1, 24.7, 25.6 et 26.0° de l'angle de diffraction 2(teta) dans un diagramme de diffraction de rayons X sur poudre ont un petit volume spécifique, sont difficiles à charger électriquement, sont faciles à manipuler et sont utiles à titre d'ingrédients pharmaceutiques actifs pour d'excellents agents antirhumatismaux.
MA31468A 2006-05-26 2008-12-12 Nouveau cristal d'acide 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]propionique MA30510B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006146220 2006-05-26

Publications (1)

Publication Number Publication Date
MA30510B1 true MA30510B1 (fr) 2009-06-01

Family

ID=38778516

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31468A MA30510B1 (fr) 2006-05-26 2008-12-12 Nouveau cristal d'acide 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]propionique

Country Status (27)

Country Link
US (1) US7977492B2 (fr)
EP (1) EP2022788B1 (fr)
JP (1) JP5117381B2 (fr)
KR (1) KR101389038B1 (fr)
CN (1) CN101454298B (fr)
AT (1) ATE479666T1 (fr)
AU (1) AU2007268771B2 (fr)
BR (1) BRPI0712909A2 (fr)
CA (1) CA2652939C (fr)
CY (1) CY1111398T1 (fr)
DE (1) DE602007008882D1 (fr)
DK (1) DK2022788T3 (fr)
EC (1) ECSP089000A (fr)
ES (1) ES2351065T3 (fr)
HR (1) HRP20100544T1 (fr)
IL (1) IL195416A (fr)
MA (1) MA30510B1 (fr)
MX (1) MX2008014906A (fr)
NO (1) NO20084632L (fr)
NZ (1) NZ573034A (fr)
PL (1) PL2022788T3 (fr)
PT (1) PT2022788E (fr)
RS (1) RS51517B (fr)
RU (1) RU2429233C2 (fr)
SI (1) SI2022788T1 (fr)
WO (1) WO2007138996A1 (fr)
ZA (1) ZA200809922B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2562170T3 (pl) * 2006-02-21 2015-03-31 Toyama Chemical Co Ltd Sposób wytwarzania estru kwasu 3-{5-[4-(cyklopentyloksy)- 2-hydroksybenzoilo]-2-[(3-okso-2-podstawionego-2,3-dihydro-1,2-benzizoksazol-6-ilo)metoksy]fenylo}- propionowego i związku pośredniego dla sposobu
NZ588128A (en) * 2008-03-27 2012-12-21 Toyama Chemical Co Ltd USE OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND TNF alpha INHIBITOR IN COMBINATION AND PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVE OR SALT THEREOF AND THE INHIBITOR
CN102014889A (zh) 2008-04-22 2011-04-13 富山化学工业株式会社 组合使用二苯甲酮衍生物或其盐和免疫抑制剂的方法以及包含这些组分的药物组合物
CN103183647B (zh) * 2011-12-28 2017-06-09 天津市国际生物医药联合研究院有限公司 3‑{[2‑[3‑氧‑(1,2‑苯并异噻唑‑6‑基)甲氧基‑5‑(2‑羟基‑4‑环戊氧基苯甲酰基)]苯基}丙酸的制备方法
CN118255728B (zh) * 2024-01-25 2024-07-30 中国医学科学院阜外医院 化合物的盐型晶型用于治疗射血分数保留的心衰的用途
CN118252824B (zh) * 2024-01-25 2024-09-17 中国医学科学院阜外医院 化合物用于治疗射血分数保留的心衰的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3042150A (en) 1960-01-26 1962-07-03 Lukawsky Michael Emergency brake and anti-skid device
WO1995001964A1 (fr) * 1993-07-06 1995-01-19 Yamanouchi Pharmaceutical Co., Ltd. Nouveau cristal de derive de benzodiazepine
AU769778B2 (en) * 1998-11-05 2004-02-05 Toyama Chemical Co. Ltd. Novel compounds and pharmaceutical use thereof
JP4976617B2 (ja) * 2000-03-17 2012-07-18 富山化学工業株式会社 新規なベンゾフェノン誘導体およびその塩
JP4554926B2 (ja) 2001-11-16 2010-09-29 富山化学工業株式会社 新規なベンゾフェノン誘導体またはその塩

Also Published As

Publication number Publication date
BRPI0712909A2 (pt) 2012-10-02
KR101389038B1 (ko) 2014-04-28
DK2022788T3 (da) 2010-12-13
US7977492B2 (en) 2011-07-12
RS51517B (en) 2011-06-30
IL195416A (en) 2012-07-31
DE602007008882D1 (de) 2010-10-14
ES2351065T3 (es) 2011-01-31
MX2008014906A (es) 2008-12-09
ECSP089000A (es) 2009-02-27
KR20090014194A (ko) 2009-02-06
HRP20100544T1 (hr) 2010-11-30
AU2007268771B2 (en) 2011-12-01
ATE479666T1 (de) 2010-09-15
EP2022788A1 (fr) 2009-02-11
SI2022788T1 (sl) 2011-01-31
RU2429233C2 (ru) 2011-09-20
EP2022788B1 (fr) 2010-09-01
IL195416A0 (en) 2009-08-03
WO2007138996A1 (fr) 2007-12-06
PL2022788T3 (pl) 2011-03-31
CN101454298B (zh) 2011-11-16
CY1111398T1 (el) 2015-08-05
ZA200809922B (en) 2010-02-24
JPWO2007138996A1 (ja) 2009-10-08
EP2022788A4 (fr) 2009-06-24
CA2652939C (fr) 2014-12-02
AU2007268771A1 (en) 2007-12-06
US20090275757A1 (en) 2009-11-05
NO20084632L (no) 2008-12-12
JP5117381B2 (ja) 2013-01-16
CA2652939A1 (fr) 2007-12-06
CN101454298A (zh) 2009-06-10
PT2022788E (pt) 2010-10-04
RU2008151778A (ru) 2010-07-10
NZ573034A (en) 2010-08-27

Similar Documents

Publication Publication Date Title
MA30510B1 (fr) Nouveau cristal d'acide 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6-yl)methoxy]propionique
RU2200158C2 (ru) Замещенные изоксазолы, фармацевтические композиции на их основе и способ подавления воспалений
NZ594122A (en) 2-Phenyl-N-(2-(6-(pyrrolidin-1-ylmethyl)thiazolo[5,4-b]pyridin-2-yl)phenyl)thiazole-4-carboxamide derivatives
NO20084634L (no) Oral sammensetnig omfattende 3-(5-(4-(cyklopentyloksy)-2-hydroksybenzoyl)-2-((3-hydrolsy-1,2-benzisoksazol-6-yl) metoksy) fenyl) propionsyre eller salt derav
BR122019020961B8 (pt) uso do ácido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]benzóico ou um sal farmaceuticamente aceitável do mesmo
SI2576523T1 (sl) Kristalinične oblike 4-(5-(3-kloro-5-(trifluorometil)fenil)-4,5-dihidro 5-(trifluorometil)-3-izoksazolil)-N-(2-okso-2-((2,2,2-trifluoroetil) amino)etil)-1 naftalenkarboksamida
RU2007132262A (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
JP2005536475A5 (fr)
JP2013531028A5 (fr)
JP2012519160A5 (fr)
PE20110568A1 (es) Agentes terapeuticos 414
JP4588998B2 (ja) 併用剤
MX2009002439A (es) Procesos para la preparacion de acidos 1,2,4-oxadiazolbenzoicos.
RU2013127155A (ru) Новые замещенные бициклические ароматические соединения в качестве ингибиторов s-нитрозоглутатион-редуктазы
JP2016534124A5 (fr)
WO2009138437A4 (fr) Conjugués de salicylés utiles pour le traitement de troubles métaboliques
WO2008127300A3 (fr) Dérivés d'oxazolidinone et leurs procédés d'utilisation
MY142268A (en) Processes for preparing biaryl boronic acids and n-protected n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide
MX2010012421A (es) 5-[5-[2-(3,5-bis(trifluormetil)fenil)-2-metilpropanoilmetilamino] -4-(4-fluoro-2-metilfenil)]-2-piridinil-2-alquil-prolinamida como antagosnistas del receptor de neurocinina 1.
JP2012520899A5 (fr)
FR2865732B1 (fr) Composes de type hydrazide et leur utilisation dans des compositions pharmaceutiques pour le traitement des maladies cardiovasculaires
JP2014532688A5 (fr)
JP2004517947A5 (fr)
EA200500802A1 (ru) Лечение латентного туберкулёза
WO2009069680A1 (fr) Composition médicinale pour traiter une tumeur du stroma gastro-intestinal (gist), et matériel et procédé pour estimer le pronostic d'un patient souffrant de tumeur du stroma gastro-intestinal